1128 Evaluation of Oral Prostaglandin E1 in Management of Ductus Dependent Congenital Heart Disease

Introduction Intravenous prostaglandin E1 (PGE1) infusion is a treatment which effect is proven in ductus dependent congenital heart disease. However, PGE1 is very expensive, needed continuous infusion and its supply is difficult by every center. When its long term use is necessary, these problems become more important. Aim To show whether oral PGE1could keep the ductus open or not till the supply of intravenous PGE1. Method Ten patients, who were admitted to newborn intensive care unit with the diagnosis of ductus dependent congenital heart disease and received oral PGE1 till the supply of intravenous PGE1, were evaluated. Results It was observed that the PO2 and SO2 levels of patients measured 2 hours after the initiation of oral PGE1 were significantly increased compared to the levels before initiation of PGE1 (p